Figure 4.

WBC in tumor bearing mice treated with PSK and docetaxel. Groups of mice (n=7) bearing established TRAMP-C2 tumors (12 days) were treated with either oral saline, subtherapeutic dose of docetaxel (5 mg/kg twice weekly), oral gavage of PSK (300 mg/kg), or a combination of docetaxel and PSK. WBC were assessed at the end of the experiment (mean ± SEM). Docetaxel alone induced a 25% reduction in WBC. Addition of PSK decreased the docetaxel-suppressive effect by ~50%, a difference that was statistically significant compared to docetaxel alone (p=0.03).